Gilead reports sinking HCV sales, Yescarta update

Gilead Sciences Inc. (NASDAQ:GILD) reported declines in HCV product sales in its 4Q17 earnings report Tuesday and also provided an update on its chimeric antigen receptor (CAR) T cell therapy, Yescarta axicabtagene ciloleucel.

HCV drugs brought in

Read the full 377 word article

User Sign In